Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-7252 · 1 trial · 2 indications
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Adverse events are reported by dose taken at time of event and not by panel or period. The adverse events for placebo are pooled over periods across panels. The number of participants who experienced at least one AE is presented.
An AE was defined as any untoward medical occurrence in a participant administered study treatment and which did not necessarily have to have had a causal relationship with this treatment. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition that was temporally associated with the use of study treatment, was also an AE. Discontinuations are reported by dose taken at time of event. The discontinuations for placebo are pooled over periods across panels. The number of participants who discontinued study treatment due to an AE is presented.
| Arm | Type | Description |
|---|---|---|
| Panel A | EXPERIMENTAL | Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 1 mg of MK-7252, 6 mg of MK-7252, 24 mg of MK-7252, 72 mg of MK-7252, and 108 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods |
| Panel B | EXPERIMENTAL | Participants receive either a single dose of MK-7252 or Placebo in a fasted state in each of five alternating treatment dosing periods as indicated. The planned dose levels include: Placebo for MK-7252, 3 mg of MK-7252, 12 mg of MK-7252, 48 mg of MK-7252, 72 mg of MK-7252, and 162 mg of MK-7252. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods |
| Panel C | EXPERIMENTAL | Participants receive either a single dose of MK-7252 or Placebo in up to 5 treatment dosing periods as indicated: Placebo for MK-7252, 120 mg of MK-7252 in a fasted state, 240 mg of MK-7252, 360 mg of MK-7252, 540 mg of MK-7252, and 120 mg of MK-7252 in a fed state. There is a minimum of a 7-day washout period between each treatment period or dose administration. The planned dose levels may be adjusted downward or replaced based on evaluation of safety, tolerability, pharmacokinetic and/or pharmacodynamic data observed after previous treatment periods |
| Name | Type | Description |
|---|---|---|
| MK-7252 | DRUG | 1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL |
| Placebo | DRUG | Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL |
Inclusion Criteria: * Male or female participants of non-childbearing potential (Note: If postmenopausal female: participant is without menses for at least 1 year and has a documented follicle stimulating hormone \[FSH\] level in the postmenopausal range at pre-trial \[screening\] - OR - If surgica...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
MK-7252 is an investigational small molecule being developed by Merck & Company, Inc. (MRK) for cancer. It is in Phase 1 clinical development and has been studied in a single completed trial. It is not an approved medicine.
MK-7252 is being developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 1 study of the compound conducted in healthy adult participants in Belgium.
MK-7252 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. The compound is investigational and has not been approved for any indication.
MK-7252 has been evaluated in one completed Phase 1 trial, NCT03326986, titled Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001). The study enrolled 24 healthy adult volunteers in Belgium and was randomized, double-blind, and controlled.
MK-7252 is being developed as an oncology candidate for cancer. Its only completed clinical study enrolled healthy adult volunteers rather than patients, so it has not yet been tested for antitumor activity in a patient population.